Keywords:
COVID-19, протромбиновый индекс, ферритин, эноксапарин.References
Cuker A., Tseng EK., NieuwlaatR. et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.Blood Adv (2021) 5 (3): 872–888.
Di Micco P, Russo V, Carannante N, Imparato M, Rodolfi S, Cardillo G, et al. Clotting factors in COVID-19: epidemiological association andprognostic values in different clinical presentations in an Italian Cohort.JClin Med. (2020) 9:1371.
Fontana P, Casini A, Robert-Ebadi H, Glauser F, Righini M, Blondon M. Venous thrombo-embolism in COVID-19: systematic review of reported risks and current guidelines. Swiss Med Wkly. (2020) 150:w20301.
Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. (2020) 8:e46–7.
Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. ESC Scientific Document Group developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. (2020) 41:543–603.
Levi M., M. Scully, How I treat disseminated intravascular coagulation. Blood. (2018) 131:845–54.
McCloskey B, Heymann DL. SARS to novel coronavirus: old lessons and new lessons. Epidemi-olInfect. (2020) 148:e22.
Moores LK, Tritschler T, Brosnahan S, Car-rier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. (2020) 158:1143–63.
Russo V, Bottino R, Carbone A, Rago A, Papa AA, Golino P, et al.COVID-19 and heart: from clinical features to pharmacological implications.JClin Med. (2020) 9:E1944.
Russo V, Rago A, Carbone A, Bottino R, Ammendola E, Della Cioppa N, et al. Atrial fibrillation in COVID-19: from epidemiological association to pharmacological implications. J CardiovascPharmacol. (2020) 76:138–45.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J ThrombHaemost. (2020) 18:1094– 9.
Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366(01):9–19.
Eikelboom JW, Connolly SJ, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377(14):1319–1330.
Cohen AT, Spiro TE, Büller HR, et al; MA-GELLAN Investigators. Rivaroxaban for thrombo-prophylaxis in acutely ill medical patients. N Engl J Med 2013;368(06):513–523.
Spyropoulos AC, Ageno W, Albers GW, et al; MARINER Investigators. Rivaroxabanfor thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018;379(12):1118–1127.
Cohen AT, Harrington RA, Goldhaber SZ, et al; APEX Investigators. Extended thromboprophylaxis
laxis with betrixaban in acutely ill medical patients. NEnglJMed 2016;375(06):534–544.
Временные методические рекомендации по профилактике, диагностике, лечению и реабилитации прикоронавирусной инфекции (COVID-19), Версия 8, 2020. (03.09.2020).
Громов А.А., КручининаМ.В., Рабко А.В.Коронавирусная болезнь COVID-19: неиспользованные возможности терапии.РМЖ. 2020, №9. С.2-6.